On January 17, 2019, Zhangjiang Hi-Tech Park signed a number of major projects. Shanghai Tianci International Pharmaceuticals Co., Ltd. signed cooperation agreements with Fosun Kite Biotechnology Co., Ltd. and Shanghai Green Valley Pharmaceutical Co., Ltd. respectively. Two original innovative drugs, Yescarta, a new drug of Fosun Kate, and sodium oligo-mannurarate capsules (GV971) will be industrialized in Zhangjiang Hi-Tech Park.
Yescarta, a new drug of Fosun Kate, is the CAR-T therapy and the leading treatment technology of malignant tumor in the world, which is expected to fill the domestic gap. Jointly developed by Green Valley Pharmaceutical, Ocean University of China and Shanghai Institute of Materia Medica, Chinese Academy of Sciences, GV971 is the first new drug for Alzheimer's disease in the world in 16 years. It has completed phase III clinical trial and its production license is applied. The product will be put into production soon. In the future, the two drugs will be manufactured on the Tianci International sharing pharmaceutical platform, which will be officially put into operation, and fully marketed. It is known that the sharing pharmaceutical platform has rarely been reported before.
Known as “China’s Medicine Valley”, Zhangjiang has always assumed the mission of national new drug R & D. At present, Zhangjiang has become a symbolic science and technology park with rich R&D resources, rapid growth in the number of innovative achievements and the first breakthrough of new technologies and new models. In recent years, Zhangjiang's innovative medicine achievements are mushrooming, with new drugs coming out continuously. Tang Shiqing, director of the Science, Technology and Economic Commission of Shanghai Pudong New Area, said that after more than 20 years of development, Zhangjiang's biomedical industry has entered a mature stage. It is world-renowned in the field of medical research and development. However, for a long time, Zhangjiang haven’t had a strong ability of production and manufacturing.
How can Zhangjiang guarantee the production of original and innovative drugs when the production resources are very scarce? How can it transform "Zhangjiang R&D" into "Zhangjiang Intelligent Manufacturing"? How can it gradually develop the cost center of pharmaceutical R&D into the profit center of Chinese innovative enterprises?...... Through market-oriented innovation mode and integrating R&D, production and sales resources, a "flexible, open and giving" sharing pharmaceutical platform can be formed, which can address the "last mile" of the industrialization of innovative drugs. This means that in the future, Shanghai will not only be the "origin" of innovative drugs, but also build the whole industry chain ecology of innovative drugs.
It is known that new drugs are all found under the stages of drug discovery, preclinical research, clinical research, production, commercialization and so on; Traditional pharmaceutical factories are more insular, often only producing their own drugs without any social service and creativity. The sharing pharmaceutical platform builds a new biomedical ecological chain, including pharmaceutical production services, clinical research services, drug sales services, drug registration services and financial services. The industry chain has solved the biggest pain point in the current biomedical industry.
Under the guidance of the national drug Marketing Authorization Holder (MAH) policy, Tianci International has built a “Science & Innovation Dream Works” through many years of hardships, which will be put into production. Covering 211 mu and a construction area of 280,000 square meters, Tianci “Science & Innovation Dream Works” has 20 standard workshops and can undertake 80 GMP production lines at most.
Tang Shiqing believes that the innovative development of Tianci sharing pharmaceutical platform shows Zhangjiang's conception and innovation of a new round of energy level upgrading of biomedical industry in the future. The attempt and innovation of Tianci sharing platform will help Zhangjiang pharmaceutical industry move from innovation chain to value chain, and play a decisive role in the positive capital recovery and subsequent R&D upgrading of innovative enterprises. At the same time, the sharing pharmaceutical platform makes Zhangjiang biomedical industry form a real closed-loop, or will open a new era of pharmaceutical industry.
